



Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
Phone: 858-875-8600
Fax: 858-875-8650
www.orexigen.com

March 12, 2018

Dear Healthcare Professional

As one of our valued customers, we want to share with you that Orexigen Therapeutics, Inc. has announced the decision to sell all of the assets of the company by the end of June using a structured process through Chapter 11 of the U.S. Bankruptcy Code. We wanted to take this opportunity to reassure you that we remain committed as ever to serving you and your patients. This decision does not affect our Direct Account contracting for practice dispensing program. Contrave will continue to be available for you to purchase and dispense for your patients.

Orexigen's normal day-to-day operations will continue without interruption. We remain completely focused on serving our customers and maintaining our valued relationships to ensure that your patients are able to continue to receive Contrave.

Orexigen was founded on the premise of helping to improve the health and lives of patients struggling to lose weight, and we remain as committed as ever to that mission. Contrave[®] (naltrexone HCl and bupropion HCl extended release) is the #1 prescribed weight loss brand and almost 800,000 patients have benefitted from CONTRAVE since launch¹, but we also know that many more patients could benefit. With our continued investment, and your continued support, we confidently intend to serve the growing patient demand.

CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m² or greater (obese), or adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults. CONTRAVE patients should be monitored for suicidal thoughts and behaviors. In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported. CONTRAVE is not approved for use in children under the age of 18.

Very truly yours,

Michael Narachi
President & Chief Executive Officer

1. Source: IQVIA NPA data Sept 2014 through Jan 2018 and the IQVIA Persistence and Adherence study conducted June 2016